Apollo Endosurgery, Inc. (NASDAQ:APEN) is reporting second quarter financial results on Tuesday 4th August 2020, after market close.
According to analysts surveyed by Thomson Reuters, APEN is expected to report 2Q20 loss of $ 0.33 per share from revenue of $ 5.19 million.
For the full year, analysts anticipate top line of $ 34.89 million, while looking forward to loss of $ 1.36 per share bottom line.
Previous Quarter Performance
Apollo Endosurgery, Inc. reported loss for the first quarter of $ 0.49 per share, from the revenue of $ 10.72 million. The quarterly revenues down 18.85 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.45 per share from $ 8.73 million in revenue. The bottom line results missed street analysts by $ 0.04 or 8.89 percent, at the same time, top line results outshined analysts by $ 1.99 million or 22.79 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of Apollo Endosurgery, Inc.
Stock Performance
According to the previous trading day, closing price of APEN was $ 1.65, representing a 33.06 % increase from the 52 week low of $ 1.24 and a 56.46 % decrease over the 52 week high of $ 3.79.
The company has a market capital of $ 39.07 million and is part of the Healthcare sector and Medical Devices industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”APEN” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Apollo Endosurgery, Inc. will be hosting a conference call at 4:30 PM eastern time on 4th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.apolloendo.com
Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. Its products include OverStitch and OverStitch Sx Endoscopic Suturing System that enables advanced endoscopic procedures by allowing physicians to place full thickness sutures and secure the approximation of tissue through a flexible endoscope; Orbera365 Managed Weight Loss System; and the BIB for the treatment of overweight and obese adults. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Brazil, Australia, and other European countries.
